WO2007134595A3 - Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin - Google Patents

Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin Download PDF

Info

Publication number
WO2007134595A3
WO2007134595A3 PCT/DE2007/000940 DE2007000940W WO2007134595A3 WO 2007134595 A3 WO2007134595 A3 WO 2007134595A3 DE 2007000940 W DE2007000940 W DE 2007000940W WO 2007134595 A3 WO2007134595 A3 WO 2007134595A3
Authority
WO
WIPO (PCT)
Prior art keywords
weight
cytostatic
tumour
physiology
cis
Prior art date
Application number
PCT/DE2007/000940
Other languages
English (en)
French (fr)
Other versions
WO2007134595A2 (de
Inventor
Hannsjoerg Sinn
Original Assignee
Albupharm Heidelberg Gmbh & Co
Hannsjoerg Sinn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albupharm Heidelberg Gmbh & Co, Hannsjoerg Sinn filed Critical Albupharm Heidelberg Gmbh & Co
Priority to EP07764344A priority Critical patent/EP2026789A2/de
Publication of WO2007134595A2 publication Critical patent/WO2007134595A2/de
Publication of WO2007134595A3 publication Critical patent/WO2007134595A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die Erfindung betrifft eine pharmazeutische Zusammensetzung enthaltend: a) 0,01 bis 4 Gew.-% eines Konjugates eines niedermolekularen Zytostatikums mit zwei oder mehr reaktiven Gruppen mit einem humanverträglichen Protein, wobei das Gewichtsverhältnis Protein zu Zytostatikum im Konjugat bei 20:1 oder hoher liegt, b) 0 bis 0, 9 Gew.-% NaCl, c) 0 bis 5 Gew.-% eines Stabilisierungsadditivs, d) 0 bis 5 Gew.-% galenischer Zusatz- und/oder Hilfsstoffe, welche von den Komponenten b) und c) verschieden sind, e) 0 bis 5 Gew.-% einer von der Komponente a) verschiedenen pharmakologisch und/oder diagnostisch wirksamen Substanz oder einer Mischung verschiedener solcher Substanzen, f) 19,9 bis 99,9 Gew.-% Wasser, wobei sich die Komponenten a) bis e) stets zu 100% addieren. Die Erfindung betrifft des Weiteren Verwendungen solcher Zusammensetzungen und Verfahren zu deren Herstellung.
PCT/DE2007/000940 2006-05-23 2007-05-23 Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin WO2007134595A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07764344A EP2026789A2 (de) 2006-05-23 2007-05-23 Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006024528.8 2006-05-23
DE102006024528A DE102006024528A1 (de) 2006-05-23 2006-05-23 Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin

Publications (2)

Publication Number Publication Date
WO2007134595A2 WO2007134595A2 (de) 2007-11-29
WO2007134595A3 true WO2007134595A3 (de) 2008-10-16

Family

ID=38521760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2007/000940 WO2007134595A2 (de) 2006-05-23 2007-05-23 Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin

Country Status (3)

Country Link
EP (1) EP2026789A2 (de)
DE (1) DE102006024528A1 (de)
WO (1) WO2007134595A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020171A1 (en) * 2012-08-03 2014-02-06 Boehringer Ingelheim International Gmbh Buffer capacity of antibodies
US10111936B2 (en) 2015-01-19 2018-10-30 Theralase Technologies, Inc. Metal-glycoprotein complexes and photodynamic therapy of immune privileged sites with same
CN107427579A (zh) * 2015-01-19 2017-12-01 锡拉莱斯科技有限公司 金属‑糖蛋白复合物及其作为化学治疗化合物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010446A2 (en) * 1999-08-09 2001-02-15 Pharmacia & Upjohn S.P.A. Formulations for parenteral use of estramustine phosphate and albumin
DE19957688A1 (de) * 1999-11-30 2001-06-13 Deutsches Krebsforsch Konjugate von cis-Platin(II)-Derivaten, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2005094895A1 (de) * 2004-04-02 2005-10-13 Albupharm Heidelberg Gmbh & Co Herstellung und verwendung des konjugats methotrexat-albumin als mittel zur immunsuppression bei gvhd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010446A2 (en) * 1999-08-09 2001-02-15 Pharmacia & Upjohn S.P.A. Formulations for parenteral use of estramustine phosphate and albumin
DE19957688A1 (de) * 1999-11-30 2001-06-13 Deutsches Krebsforsch Konjugate von cis-Platin(II)-Derivaten, Verfahren zu ihrer Herstellung und ihre Verwendung
WO2005094895A1 (de) * 2004-04-02 2005-10-13 Albupharm Heidelberg Gmbh & Co Herstellung und verwendung des konjugats methotrexat-albumin als mittel zur immunsuppression bei gvhd

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRYNDA-LEMIESZ L ET AL: "Effect of cis-, trans-diamminedichloroplatinum(II) and DBP on human serum albumin.", JOURNAL OF INORGANIC BIOCHEMISTRY 1999 NOV-DEC, vol. 77, no. 3-4, November 1999 (1999-11-01), pages 141 - 146, XP002491018, ISSN: 0162-0134 *

Also Published As

Publication number Publication date
EP2026789A2 (de) 2009-02-25
WO2007134595A2 (de) 2007-11-29
DE102006024528A1 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
EP2471886A3 (de) Zusammensetzungen für geringe Erderwärmung
MA32394B1 (fr) Composes pegyles d&#39;insuline lispro
NI200800299A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias.
ZA200707973B (en) Low amounts of high molecular weight polymer for enhancing viscosity of aqueous/aqueous biphasic liquids
WO2012084624A9 (en) Compositions of fat-soluble active ingredients containing plant protein-soy polysaccharide complexes
DE602005021963D1 (de) Teilchenförmige zusammensetzungen und ihre herstellung
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2008136865A3 (en) (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
EP1561760A3 (de) Salz von Heparin mit niedrigem Molekulargewicht mit Triethanolamin
DE602005016803D1 (de) Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
IL206514A (en) History of triazole oxadiazole, their preparation and their pharmaceutical preparations
CA2696335A1 (en) Gel containing pirfenidone
SG170120A1 (en) Compositions containing riboflavin and sesamin-class compounds
WO2005107773A3 (en) Solid dosage form of wetted heparin
WO2007134595A3 (de) Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin
DK2208734T3 (da) Levnedsmiddelmateriale til inhibering af dannelsen af osteoclast
TW200800993A (en) Organic compounds
HK1123986A1 (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
WO2013066208A3 (ru) Фармацевтическая композиция на основе наномицелл, содержащих эпигаллокатехингаллат, и ее применение
WO2009065507A3 (en) Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof
WO2009065946A3 (de) Pharmazeutisches kit aus einer öl/wasser-emulsion und einer festen zusammensetzung
RU2445289C1 (ru) Сырьевая смесь для изготовления керамзита
WO2007044185A3 (en) Liquid cure promoter compositions with suppressed solids forming tendencies and their uses
RU2338719C1 (ru) Сырьевая смесь

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07764344

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007764344

Country of ref document: EP